Anesthesia for Patients with Kidney Disease: Fluid Therapy and Drug Choices

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Fluid Therapy is Paramount: Balanced crystalloids (e.g., Lactated Ringer's, Normosol-R) are preferred over 0.9% saline to avoid hyperchloremic acidosis and renal vasoconstriction. Fluid administration must balance the risk of hypoperfusion against volume overload, with rates typically 3-5 mL/kg/hour for maintenance, and boluses of 10-15 mL/kg for hypotension.
• Maintain Mean Arterial Pressure (MAP): Target MAP above 65-70 mm Hg is critical to prevent renal medullary hypoxia, as autoregulation is impaired in renally compromised patients. Direct arterial blood pressure monitoring is recommended for high-risk patients.
• Drug Selection and Dosing: Prioritize drugs with hepatic metabolism or non-renal elimination pathways. For renally excreted drugs (e.g., some opioids, neuromuscular blockers), extend dosing intervals or choose alternatives. Avoid NSAIDs due to their renal vasoconstrictive effects.
• Minimize Perioperative Injury: Avoid hyperglycemia (blood glucose > 160 mg/dL is associated with increased ischemic renal injury). Monitor intraoperative glucose and manage diabetes carefully. Consider multimodal analgesia to reduce sympathetic outflow and nociceptive input.
• Preoperative Assessment is Crucial: Staging of renal disease (e.g., IRIS stages), baseline creatinine, SDMA, electrolytes (especially potassium), and blood pressure are essential for anesthetic planning. Anemia (PCV < 20%) increases the risk of renal medullary hypoxia and may warrant transfusion.
• Vigilant Intraoperative and Recovery Monitoring: Continuous assessment of blood pressure, urine output (catheterize for procedures >2 hours or Stage 3/4 disease), and perfusion parameters is vital. Oliguria (output < 1-2 mL/kg/hour) requires investigation of perfusion status and fluid balance.

This article addresses anesthetic planning for dogs and cats with chronic kidney disease (CKD) or acute kidney injury (AKI), with emphasis on fluid therapy, blood pressure management, and drug selection based on renal elimination pathways. It is written for practicing veterinarians who need a decision framework for preoperative assessment, intraoperative monitoring, and recovery care in renally compromised patients. The content integrates consensus guidance from the AAHA Anesthesia and Monitoring Guidelines for Dogs and Cats with published evidence on anesthetic effects on renal perfusion and oxygenation.

The central clinical question is how to maintain renal oxygen supply-demand balance during general anesthesia. The kidney receives a high fraction of cardiac output but extracts oxygen inefficiently, leaving the medulla vulnerable to hypoperfusion. Anesthetic drugs alter renal blood flow, glomerular filtration, and tubular function through direct vascular effects and through changes in sympathetic outflow. Understanding these mechanisms allows the anesthetist to select agents and fluid strategies that minimize additional injury in a patient whose renal reserve is already reduced.

At a Glance

Renal Physiology Under Anesthesia

The kidney autoregulates blood flow across a range of perfusion pressures, but this capacity is impaired in chronic kidney disease and during systemic inflammation. When mean arterial pressure falls below the autoregulatory threshold, glomerular filtration declines and medullary perfusion becomes critically dependent on the balance between vasoconstrictor and vasodilator influences. Anesthetic agents can disrupt this balance directly.

Volatile anesthetics and propofol differ in their effects on renal sympathetic nerve activity. Large animal studies reviewed by Franzén and colleagues demonstrate that volatile anesthesia stimulates the renal sympathetic nervous system more than intravenous propofol anesthesia, resulting in decreased water and sodium excretion and reduced renal perfusion and oxygenation. The authors note that increased renal sympathetic nerve activity may impair excretory function and induce structural injury in ischemic AKI models. Whether these differences translate to clinically meaningful outcomes in humans or companion animals remains unresolved, but the mechanistic evidence supports caution with volatile agent dosing in renally compromised patients.

Alpha-2 agonists such as medetomidine produce dose-dependent vasoconstriction and reductions in cardiac output. Contrast enhanced ultrasound studies in healthy beagles show that medetomidine, alone or combined with tiletamine-zolazepam, delays time to peak enhancement and decreases the upslope of renal medullary perfusion compared with conscious animals. These changes indicate reduced perfusion velocity and may reflect clinically relevant decreases in medullary blood flow. The clinical significance in patients with preexisting renal disease is likely greater than in healthy research subjects.

The Sympathetic Nervous System and Perioperative AKI

Postoperative acute kidney injury occurs in approximately 7% of patients undergoing non-cardiac surgery with general anesthesia, according to the review by Franzén and colleagues. The pathogenesis is multifactorial, but renal sympathetic activation appears to contribute through several mechanisms: direct vasoconstriction of afferent arterioles, stimulation of renin release, increased tubular sodium reabsorption with elevated oxygen demand, and enhanced susceptibility to ischemic injury.

This framework explains why blood pressure management alone is insufficient. Maintaining perfusion pressure while ignoring sympathetic tone or oxygen demand can still result in medullary hypoxia. The anesthetist should consider the total physiologic stress of the procedure, including surgical stimulation, hypovolemia, and pain, as contributors to renal sympathetic outflow. Multimodal analgesia, as outlined in the WSAVA Global Pain Council Guidelines, may reduce nociceptive input and thereby limit sympathetically mediated renal vasoconstriction.

Ischemia Reperfusion Injury and Modifiable Factors

Renal ischemia reperfusion injury is a final common pathway in perioperative AKI. The injury sequence involves endothelial dysfunction, loss of nitric oxide bioavailability, medullary hypoxia, cortical ATP depletion, and tubular epithelial cell stress. Large animal models of cardiopulmonary bypass demonstrate that anemia during bypass worsens this injury, but transfusion itself can cause renal injury characterized by endothelial damage and platelet activation. The clinical translation is that neither severe anemia nor unnecessary transfusion is benign, and the optimal hemoglobin threshold for renally compromised patients remains uncertain.

Hyperglycemia is a modifiable factor with direct relevance to anesthesia. A prospective study of living donor renal transplantation found that recipient blood glucose above 160 mg/dL at the time of allograft reperfusion was associated with increased neutrophil gelatinase-associated lipocalin, a marker of renal ischemic injury. The same predictors were associated with slower fall in creatinine on postoperative day two. While transplant recipients represent an extreme model, the finding supports intraoperative glucose monitoring and avoidance of hyperglycemia in any patient with renal disease.

Drug Elimination and Dosing Logic

Renal excretion is the primary elimination pathway for several drugs used in anesthetic practice, including some opioids, neuromuscular blocking agents, and their active metabolites. The clinical consequence of reduced glomerular filtration is prolonged drug effect, not necessarily increased peak effect. For drugs with a wide therapeutic index, this may require no adjustment. For drugs with narrow margins, dosing intervals should be extended or alternative agents selected.

Current formularies and label references must be consulted for specific dosing recommendations, as published ranges vary by species, formulation, and route. The MSD Veterinary Manual provides species-specific pharmacology summaries that are useful for cross-checking elimination pathways and contraindications. The general principle is to prefer drugs with hepatic metabolism or balanced elimination when renal function is severely reduced, and to titrate to effect instead of administering fixed doses based on body weight alone.

Fluid Therapy Principles

Fluid therapy in the renally compromised anesthetized patient serves three purposes: restoration of effective circulating volume, maintenance of renal perfusion pressure, and replacement of ongoing losses. Balanced crystalloids are generally preferred over 0.9% saline because saline administration produces hyperchloremic metabolic acidosis and renal vasoconstriction. The rate of administration depends on the patient's hydration status, cardiovascular reserve, and the anticipated fluid losses of the procedure.

The risk of volume overload must be balanced against the risk of hypoperfusion. Patients with CKD often have impaired urine concentrating ability and may be volume contracted at presentation. Patients with oliguric or anuric AKI cannot excrete a fluid load and may develop pulmonary edema if resuscitation is overly aggressive. Serial assessment of body weight, central venous pressure when available, and urine output guides therapy more reliably than static parameters such as skin turgor.

Preoperative Assessment and Risk Stratification

The preoperative evaluation of a renal patient begins with staging the disease, not with choosing drugs. International Renal Interest Society (IRIS) stage, current laboratory values, and trends over time determine how aggressively fluid therapy must be pursued and which drugs require dose adjustment. A patient with stable IRIS Stage 2 chronic kidney disease and normal perfusion parameters presents a different anesthetic challenge than a patient with Stage 4 disease, uremic gastritis, and dehydration.

The minimum database for anesthetic planning includes creatinine, blood urea nitrogen, symmetric dimethylarginine (SDMA), potassium, phosphorus, packed cell volume, total protein, and urine specific gravity. Blood pressure measurement is mandatory. A patient with hypertension and renal disease may have concurrent target organ damage that affects anesthetic risk. Electrocardiography is indicated when potassium is elevated or when cardiac disease is suspected.

The physical examination should focus on hydration status, mucous membrane color, capillary refill time, and body condition. Muscle condition scoring matters because loss of muscle mass lowers creatinine production and can mask the severity of renal dysfunction. A creatinine of 2.5 mg/dL in a cachectic patient may represent more substantial loss of function than the same value in a well-muscled patient.

Decision points that change the anesthetic plan include the presence of hyperkalemia, anemia, hypoproteinemia, and concurrent conditions such as diabetes mellitus or cardiac disease. Hyperkalemia above 5.5 mEq/L warrants preoperative treatment and intraoperative monitoring. Anemia with a packed cell volume below 20% increases the risk of inadequate oxygen delivery to the renal medulla, a region already vulnerable to hypoxic injury. The AAHA anesthesia and monitoring guidelines recommend a complete preanesthetic assessment that includes laboratory evaluation and physical status classification, with the understanding that renal disease modifies both risk and monitoring intensity.

Intraoperative Fluid Selection and Rate

Crystalloid choice in the renal patient balances the need for volume support against the risk of worsening electrolyte abnormalities. Balanced isotonic crystalloids such as lactated Ringer solution or Normosol-R are appropriate for most patients. Normal saline (0.9% NaCl) is reserved for specific indications, primarily hyperkalemia with electrocardiographic changes, because it contains no potassium. The chloride load of saline, however, can contribute to metabolic acidosis and renal vasoconstriction, so it should not be used as the default fluid in renal patients.

The maintenance fluid requirement in the anesthetized renal patient is lower than textbook maintenance calculations suggest. General anesthesia reduces metabolic rate and renal blood flow, and overzealous fluid administration does not protect the kidney from ischemic injury. The MSD Veterinary Manual notes that fluid therapy in patients with renal disease must account for ongoing losses, hydration deficits, and maintenance needs separately, and that the anesthetized patient cannot communicate thirst or discomfort that would signal inadequate volume.

A practical approach is to calculate the dehydration deficit, replace half of it over the first hour if the patient is hypotensive or significantly dehydrated, and then transition to a rate that replaces maintenance plus estimated ongoing losses. For a normotensive, adequately hydrated patient, a rate of 3 to 5 mL/kg/hour is often sufficient. Hypotension, defined as mean arterial pressure below 60 to 65 mm Hg, requires a fluid bolus of 10 to 15 mL/kg over 10 to 15 minutes, repeated once if needed, before vasopressor therapy is considered.

Colloids are not first-line therapy in the renal patient. Synthetic colloids such as hydroxyethyl starch have been associated with acute kidney injury in human patients and should be avoided in veterinary patients with preexisting renal disease. Blood products are preferred when volume support and oxygen-carrying capacity are both needed. The relationship between anemia and renal injury is well documented in the cardiac surgery literature, where reversal of anemia with allogenic red blood cell transfusion prevented post-cardiopulmonary bypass acute kidney injury in a swine model, although transfusion itself carried independent renal risk reversal of anemia with allogenic RBC transfusion in a swine cardiopulmonary bypass model. In the veterinary patient with renal disease and a packed cell volume below 20%, a transfusion of packed red blood cells or whole blood should be considered before or during anesthesia.

Blood Pressure Management and Monitoring

Blood pressure monitoring is the single most important intraoperative parameter in the renal patient. The kidney autoregulates blood flow across a range of mean arterial pressures, but anesthesia, vasodilation, and preexisting renal disease narrow this range. Sustained mean arterial pressure below 65 mm Hg reduces glomerular filtration and can precipitate acute kidney injury on top of chronic disease.

Direct arterial blood pressure measurement is preferred in patients with significant renal disease, particularly those with Stage 3 or 4 disease, because oscillometric and Doppler methods become less accurate at the extremes of pressure. An arterial catheter also provides access for blood gas sampling, which is valuable when acid-base status is labile.

The choice of induction and maintenance agents affects blood pressure. Propofol causes dose-dependent vasodilation and myocardial depression. Ketamine preserves sympathetic tone and is useful in patients with cardiovascular instability, but it is partially renally excreted and its metabolites accumulate with repeated dosing. Etomidate provides hemodynamic stability but suppresses adrenal function, which may be undesirable in a stressed patient. The AAHA guidelines emphasize that the induction agent should be chosen based on the patient's cardiovascular status, with dose reduction in patients with decreased protein binding or altered volume of distribution.

Vasopressor therapy is indicated when fluid resuscitation has failed to restore mean arterial pressure above 60 to 65 mm Hg. Norepinephrine is the first-line vasopressor in most protocols. Vasopressin is an alternative that may be particularly useful in patients with vasodilatory shock, but it causes renal vasoconstriction at higher doses and should be used cautiously. Dobutamine is preferred when hypotension is accompanied by low cardiac output.

Drug Selection and Dose Adjustment

Drug selection in the renal patient follows a simple principle: choose agents that are metabolized by the liver or cleared by nonrenal routes, and reduce doses of drugs that are renally excreted. The MSD Veterinary Manual provides species-specific pharmacology data that should be consulted for each drug before administration.

Opioids are generally safe in renal patients. Morphine has an active metabolite, morphine-6-glucuronide, that accumulates with renal dysfunction and can cause prolonged sedation and respiratory depression. Hydromorphone, methadone, and fentanyl are preferable because their metabolites are less active or shorter acting. Buprenorphine is a reasonable choice for moderate pain because it has a ceiling effect on respiratory depression and its clearance is primarily hepatic.

Nonsteroidal anti-inflammatory drugs are contraindicated in patients with significant renal disease. They reduce renal perfusion by inhibiting prostaglandin synthesis, and the kidney relies on prostaglandins to maintain blood flow when perfusion pressure falls. The WSAVA Global Pain Council Guidelines recommend multimodal analgesia that reduces reliance on any single drug class, which is particularly important when NSAIDs are unavailable.

The following table summarizes drug selection considerations for common anesthetic agents in renal patients:

Dexmedetomidine deserves specific mention. It reduces sympathetic outflow and decreases renal blood flow, which would seem to make it a poor choice in renal patients. However, a clinical study of dexmedetomidine pretreatment in patients undergoing cardiopulmonary bypass demonstrated attenuation of acute kidney injury and reduced endoplasmic reticulum stress in both human patients and a rat model. The protective effect appears to be mediated through reduced oxidative stress and apoptosis, not through improved renal perfusion. In veterinary patients, the decision to use dexmedetomidine must weigh its hemodynamic effects against its potential organ-protective properties. It is best reserved for healthy patients with mild renal disease, and it should be avoided in patients with Stage 3 or 4 disease or in those with hypotension.

Intraoperative Glucose Control

Hyperglycemia is an underappreciated risk factor for renal injury in the perioperative period. A prospective study of living donor renal transplantation found that recipient blood glucose above 160 mg/dL at the time of allograft reperfusion was associated with increased neutrophil gelatinase-associated lipocalin, a marker of ischemic renal injury intraoperative hyperglycemia and ischemia reperfusion injury in renal transplantation. The same study found that elevated glucose was associated with slower fall in creatinine on postoperative day 2.

In veterinary patients, intraoperative hyperglycemia occurs most commonly in diabetic patients, but it can also develop in nondiabetic patients receiving dextrose-containing fluids or those under the influence of drugs that impair insulin secretion. Blood glucose should be measured at induction and then every 30 to 60 minutes during anesthesia in patients with renal disease, particularly those with diabetes. Dextrose-containing fluids should be avoided unless the patient is hypoglycemic. If hyperglycemia develops, the underlying cause should be addressed before insulin is administered, because insulin requirements are unpredictable in the anesthetized patient.

Recovery and Postoperative Monitoring

The recovery period is a continuation of the anesthetic event. Renal patients are at risk for hypothermia, which causes vasoconstriction and reduces renal blood flow. Active warming should continue until the patient is normothermic. Pain management should be continued with opioids and local anesthetics, but NSAIDs remain contraindicated.

Urine output should be monitored in patients with significant renal disease. A urinary catheter is appropriate for procedures lasting more than 2 hours or for patients with Stage 3 or 4 disease. Oliguria, defined as urine output below 1 to 2 mL/kg/hour, warrants investigation of perfusion status, blood pressure, and fluid balance before diuretics are considered. The AAHA guidelines recommend that monitoring continue into the recovery period until the patient is stable, with particular attention to temperature, blood pressure, and pain score.

Documentation should include the fluid type and rate, total volume administered, blood pressure readings at regular intervals, urine output if measured, blood glucose values, and any vasopressor or inotrope administration. This record allows the attending clinician to assess whether intraoperative management contributed to postoperative changes in renal function and provides a basis for adjusting the plan in future anesthetics.

Recognized Complications and Early Detection

Acute kidney injury in the perioperative period can evolve silently. The earliest detectable changes are often laboratory-based instead of clinical. Serial measurement of creatinine, symmetric dimethylarginine (SDMA), and urine output provides the most practical surveillance in small animal patients. A rising creatinine of 0.3 mg/dL or more within 48 hours, or a reduction in urine output below 0.5 mL/kg/hour for six consecutive hours, should trigger investigation instead of observation.

Hypotension remains the most common reversible contributor to renal hypoperfusion. Mean arterial pressure below 60 to 65 mm Hg in dogs and cats under anesthesia is associated with impaired renal autoregulation. Detection requires direct arterial pressure monitoring in high-risk patients, since oscillometric devices may read inaccurately during hypotension or arrhythmia. The AAHA anesthesia and monitoring guidelines recommend continuous assessment of perfusion parameters, including mucous membrane color, capillary refill time, and urine output, alongside blood pressure.

Hyperglycemia is a second modifiable complication. Intraoperative blood glucose above 160 mg/dL at the time of renal reperfusion is associated with increased ischemic injury in human renal transplantation, measured by delayed fall in neutrophil gelatinase-associated lipocalin and creatinine. The same study identified recipient age and prolonged cold ischemia as additional predictors. In veterinary patients, routine intraoperative glucose monitoring is warranted when dextrose-containing fluids are used, when the patient is diabetic, or during prolonged procedures. The MSD Veterinary Manual provides species-specific reference ranges for glucose interpretation.

Hypoxemia and hypercapnia reduce renal oxygen delivery and should be excluded when renal function deteriorates during recovery. Pulse oximetry and capnography detect these disturbances earlier than blood gas analysis alone. Anemia is a further risk factor. Experimental work in swine demonstrated that cardiopulmonary bypass-associated anemia causes renal medullary hypoxia and endothelial dysfunction, while transfusion itself produced a distinct pattern of renal injury. This paradox suggests that the threshold for transfusion should be individualized instead of formulaic.

Common Errors and Corrective Actions

The most frequent error in managing renal patients is fluid over-resuscitation. Clinicians may interpret a low urine output as volume depletion when the cause is sympathetic activation, anesthetic depth, or cardiac dysfunction. The renal sympathetic nervous system review notes that volatile anesthetics stimulate renal sympathetic outflow more than propofol, reducing water and sodium excretion. A patient under deep volatile anesthesia may have low urine output despite adequate or excessive volume status. The corrective action is to assess volume status directly using blood pressure, central venous pressure if available, lung auscultation, and serial body weight, instead of urine output alone.

A second error is the reflexive use of furosemide or mannitol to force diuresis. Neither agent protects the kidney from ischemic injury, and both can worsen prerenal azotemia if volume status is marginal. Diuretics should be reserved for specific indications such as oliguric heart failure or documented volume overload.

A third error is the assumption that a normal preoperative creatinine guarantees normal renal reserve. Many patients with chronic kidney disease have normal creatinine until substantial nephron loss has occurred. Preoperative SDMA, urine specific gravity, and blood pressure measurement provide a more complete picture. The AAHA guidelines emphasize that anesthetic risk assessment should incorporate signalment, comorbidities, and laboratory data, not a single analyte.

A fourth error is the use of nonsteroidal anti-inflammatory drugs in patients with marginal perfusion. While the WSAVA Global Pain Council guidelines support multimodal analgesia, they also caution that NSAIDs are contraindicated when renal perfusion is compromised. The clinician must confirm euvolemia and stable blood pressure before administering these agents.

Limitations of the Evidence and Divergent Expert Opinion

The evidence base for anesthetic management of renal disease in small animals is largely extrapolated from human medicine and experimental models. The finding that volatile anesthesia increases renal sympathetic activity compared with propofol comes from large animal studies, and the authors state that whether this applies to humans remains unclear. Veterinary extrapolation is therefore doubly indirect. Some anesthesiologists prefer propofol-based total intravenous anesthesia for renal patients on this basis, while others argue that the clinical significance is minor compared with blood pressure and volume management. Both positions are defensible given current evidence.

Contrast-enhanced ultrasound studies in dogs show that medetomidine-based protocols alter renal perfusion dynamics, delaying time to peak enhancement and reducing medullary upslope. Whether these changes translate into clinically meaningful injury is unknown. The contrast enhanced ultrasonography study was performed in healthy beagles, not in patients with pre-existing renal disease. Clinicians should weigh the benefits of alpha-2 agonist sedation against the theoretical risk of reduced medullary perfusion.

The role of dexmedetomidine in renal protection is similarly contested. One study in cardiac surgery patients and rats found that dexmedetomidine pretreatment attenuated acute kidney injury and endoplasmic reticulum stress after myocardial ischemia reperfusion. The dexmedetomidine pretreatment study supports a protective effect, but the mechanism and the applicability to non-cardiac surgery remain uncertain. Some experts advocate dexmedetomidine as a renal-protective adjunct, while others avoid it due to its vasoconstrictive effects.

Referral and Escalation Criteria

Referral to a specialist anesthesiologist or criticalist is warranted when a patient has stage 3 or 4 chronic kidney disease, requires emergency surgery, or has failed to maintain mean arterial pressure above 65 mm Hg despite fluid resuscitation and vasopressor support. Laboratory consultation is appropriate when serial creatinine or SDMA values are rising without an obvious cause, or when electrolyte derangements such as hyperkalemia or metabolic acidosis are refractory to initial treatment.

Regulatory reporting obligations vary by jurisdiction. The AVMA practice resources and WOAH terrestrial animal health standards describe reporting requirements for notifiable diseases and adverse events. Anesthetic complications themselves are not typically reportable, but suspected drug reactions or product failures may be. Clinicians should consult local regulatory guidance when an adverse outcome occurs.

Troubleshooting Table

Frequently Asked Questions

How should I adjust my anesthetic plan when advanced monitoring equipment is unavailable?

When direct arterial blood pressure monitoring is not possible, oscillometric or Doppler methods remain acceptable, though they are less responsive to rapid changes. The AAHA anesthesia and monitoring guidelines recommend that blood pressure be measured at least every 5 minutes in any patient receiving general anesthesia. In a renal patient, prioritize urine output measurement, serial body weight, and packed cell volume or total solids to track fluid shifts. Capnography and pulse oximetry provide indirect perfusion information. If these are also absent, reduce anesthetic depth to the minimum required for the procedure, extend monitoring intervals, and document heart rate, mucous membrane color, and capillary refill time more frequently. The AVMA practice resources emphasize that monitoring adequacy depends on the observer's vigilance more than the equipment available.

What fluid strategy is appropriate when a patient has concurrent cardiac disease?

Renal patients with cardiac compromise present competing priorities. The kidney needs perfusion pressure and oxygen delivery, while the heart tolerates volume loading poorly. A balanced crystalloid at a conservative maintenance rate, guided by serial blood pressure and urine output, is the most defensible starting point. Colloids may be considered for hypotension refractory to crystalloids, but their use in patients with endothelial injury carries risk. The WSAVA global pain guidelines remind clinicians that analgesic choices also affect volume status, since nonsteroidal anti-inflammatory drugs can reduce renal perfusion. Monitor central venous pressure if available, and reassess the fluid plan at least every 30 minutes. A patient that becomes hypertensive with fluid administration needs slower rates, not necessarily vasopressors.

How does anesthetic management differ in cats compared with dogs?

Cats have a smaller renal reserve and a higher baseline sympathetic tone, making them more sensitive to hypotension and to drugs that reduce cardiac output. The MSD Veterinary Manual notes that feline renal autoregulation operates over a narrower blood pressure range than in dogs. Ketamine-based protocols may preserve arterial pressure but can increase myocardial oxygen demand. Opioids are generally well tolerated. Cats also concentrate urine more efficiently, so a given fluid deficit produces less obvious clinical change until decompensation is advanced. Recovery should include early provision of food and water, since cats that do not eat for 24 hours develop hepatic lipidosis, which further complicates metabolic management. The AAHA anesthesia guidelines recommend species-specific monitoring thresholds instead of a single standard for both.

What should I document in the medical record for a renal patient under anesthesia?

Record the preoperative creatinine, urea, and urine specific gravity, plus the baseline blood pressure. During anesthesia, document every fluid bolus and rate change, all blood pressure readings, urine output if a catheter is placed, and any hypotensive episode lasting more than 5 minutes. Note the total dose of each drug administered, also the induction dose. The AVMA practice resources advise that the medical record should allow another clinician to reconstruct the entire anesthetic event without asking the original anesthetist. In the recovery period, record time to sternal recumbency, first urination, and any vomiting. This documentation supports both clinical continuity and defensible decision-making if complications arise later.

How do I explain the increased anesthetic risk to an owner without causing undue alarm?

Use concrete language about what the kidney does during anesthesia: it receives about one quarter of cardiac output, and anesthetic drugs can reduce that flow. The AAHA anesthesia guidelines frame risk communication as a shared decision process. State that the patient's kidney function is reduced, that blood pressure will be monitored closely, and that fluids will be given to support perfusion. Explain that the specific risks are a temporary worsening of kidney values, prolonged recovery, or the need for additional treatment after surgery. Avoid percentages unless you have practice-specific data. Offer the owner a clear plan for what will be done if complications occur, including extended hospitalization and repeat blood work. This approach converts an abstract risk into a manageable plan.

When should I refer a renal patient to a specialist center?

Refer when the patient has stage 3 or 4 chronic kidney disease with unstable values, when urine output cannot be maintained despite fluid therapy, or when the planned procedure is lengthy and the practice lacks blood pressure monitoring. The WSAVA global pain guidelines note that multimodal analgesia reduces opioid requirements, but a center with 24-hour nursing care is better positioned to manage a renal crisis overnight. Refer also when the patient requires a drug that is nephrotoxic and no alternative exists, or when the clinician is uncertain about dose adjustment for a renally eliminated drug. A telephone consultation with an anesthesiologist or internal medicine specialist may resolve the issue without transfer. Document the reason for referral and the discussion with the receiving clinician.

Related Clinical & Scientific Guides

• Anesthetic Machine Leak Testing and Pressure Checks: A Step-by-Step Protocol
• Anesthetic Depth Assessment: Reflexes, Eye Position, and Ventilation
• Anesthesia for Patients with Obesity: Challenges and Solutions

References and Further Reading

• Anesthesia and the renal sympathetic nervous system in perioperative AKI.. 2022.
• Contrast enhanced ultrasonography of kidney in conscious and anesthetized beagle dogs.. 2016.
• Irreversible electroporation: a new challenge in "out of operating theater" anesthesia.. 2010.
• Dexmedetomidine pretreatment attenuates myocardial ischemia reperfusion induced acute kidney injury and endoplasmic reticulum stress in human and rat.. 2020.
• Reversal of anemia with allogenic RBC transfusion prevents post-cardiopulmonary bypass acute kidney injury in swine.. 2011.
• Intraoperative hyperglycemia augments ischemia reperfusion injury in renal transplantation: a prospective study.. 2011.
• AAHA Anesthesia and Monitoring Guidelines for Dogs and Cats. AAHA.
• WSAVA Global Pain Council Guidelines. WSAVA.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.

Related Articles

• Anesthesia for Patients with Liver Disease: Drug Metabolism and Dosing
• Anesthesia for Patients with Renal or Hepatic Disease: Drug Selection and Dosing Adjustments
• Anesthesia for Patients with Dental Disease: Extractions and Cleaning
• Anesthesia for Patients with Ear Disease: Vestibular Syndrome
• Anesthesia for Patients with Endocrine Disease: Diabetes and Hyperthyroidism

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.